1115.1000 -51.90 (-4.45%)
NSE Aug 01, 2025 15:31 PM
Volume: 103.7K
 

1115.10
-4.45%
ICICI Securities Limited
Tatva Chintan’s Q2FY23 revenue fell 27.1% YoY and EBITDA plunged 68.9% YoY due
to lower SDA sales, which seems very disappointing, but we believe this situation is
transitory.
Tatva Chintan Pharma.. has an average target of 1000.00 from 1 broker.
More from Tatva Chintan Pharma Chem Ltd.
Recommended